Pieris AG has entered into a collaboration and license agreement with Daiichi Sankyo Co. Ltd., under which Pieris will apply its Anticalin scaffold technology to discover novel Anticalins against two Daiichi Sankyo targets. Based on Pieris’ discovery and achievement of preclinical development milestones for lead Anticalin drug candidates, Daiichi Sankyo will assume responsibility for further development and marketing of the Anticalin compounds. Pieris will receive more than $10 million upfron...